NCT02397499已完成3 期
A Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat in Non-Obese Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 800
- 试验地点
- 31
- 主要终点
- Safety as measured by Physical examination, adverse events, vital signs, and laboratory tests.
研究概览
简要总结
This is a multi-center, randomized, double-blinded, placebo-controlled study evaluating the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Healthy male or non-pregnant female subjects
- •Capable of providing written consent.
- •BMI < 30 kg/m2
- •Stable diet and exercise routine
- •Central abdominal bulging that is evaluated by the clinician at least slight bulge, not flat
排除标准
- •Have had any treatment of the fat around your abdomen, including surgical procedures (tummy tuck, liposuction), injections for fat loss or treatments with devices to reduce fat in your abdomen.
- •Plan on starting a weight loss or exercise program during the study.
- •Known hypersensitivity to study drugs
研究组 & 干预措施
LIPO-202
Experimental
Experimental arm
干预措施: LIPO-202 (Drug)
Placebo
Placebo Comparator
Placebo comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Safety as measured by Physical examination, adverse events, vital signs, and laboratory tests.
时间窗: 8 weeks
Physical examination, adverse events, vital signs, and laboratory tests.
Change in the clinician reported photonumeric score
时间窗: 8 weeks post the start of treatment
Change in the patient reported global abdominal perception score
时间窗: 8 weeks post the start of treatment
次要结局
- Change in waist circumference(8 weeks post the start of treatment)
研究者
研究点 (31)
Loading locations...
相似试验
已完成
3 期
Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)Central Abdominal BulgingNCT02398188Evofem Inc.793
已完成
2 期
A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe PruritusChronic Kidney DiseasesPruritusNCT03617536Cara Therapeutics, Inc.269
终止
2 期
Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe PruritusCholestatic PruritusNCT03995212Cara Therapeutics, Inc.14
已完成
3 期
A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)Uremic PruritusNCT03422653Cara Therapeutics, Inc.378
终止
3 期
A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe PruritusChronic Kidney DiseasesPruritusNCT05342623Cara Therapeutics, Inc.286